AI Article Synopsis
- The study analyzes tumor genomes from over 10,000 cancer patients in China using advanced DNA sequencing technology to identify actionable genomic alterations.
- It compares genetic changes and tumor characteristics between Chinese and American patient populations, highlighting both similarities and differences.
- The research reveals that 64% of Chinese patients have clinically actionable genomic alterations, which could influence treatment decisions for targeted therapy and immunotherapy, aiding in personalized medicine approaches.
Article Abstract
Extending the benefits of tumor molecular profiling for all cancer patients requires a comprehensive analysis of tumor genomes across distinct patient populations worldwide. In this study, we perform deep next-generation DNA sequencing (NGS) from tumor tissues and matched blood specimens from over 10,000 patients in China by using a 450-gene comprehensive assay, developed and implemented under international clinical regulations. We perform a comprehensive comparison of somatically altered genes, the distribution of tumor mutational burden (TMB), gene fusion patterns, and the spectrum of various somatic alterations between Chinese and American patient populations. Here, we show 64% of cancers from Chinese patients in this study have clinically actionable genomic alterations, which may affect clinical decisions related to targeted therapy or immunotherapy. These findings describe the similarities and differences between tumors from Chinese and American patients, providing valuable information for personalized medicine.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308789 | PMC |
| http://dx.doi.org/10.1038/s41467-022-31780-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!